Alsaadi, 2017 - Google Patents

Identification and validation of mutated signalling pathways in cancer

Alsaadi, 2017

View PDF
Document ID
5868669398037130502
Author
Alsaadi A
Publication year

External Links

Snippet

Genome sequencing is emerging as a powerful tool to identify the molecular mechanism of cancer progression. However, the software tools to define genomic and post-genomic mutations are just in its infancy. We have used a novel software algorithm to analyse the …
Continue reading at core.ac.uk (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Cho et al. Sporadic early-onset diffuse gastric cancers have high frequency of somatic CDH1 alterations, but low frequency of somatic RHOA mutations compared with late-onset cancers
Scarfò et al. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts
Weber et al. PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice
JP2020530290A (en) Methods and Substances for Assessing and Treating Cancer
US10844436B2 (en) Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
Delespaul et al. Recurrent TRIO fusion in nontranslocation–related sarcomas
Wang et al. Search for chromosome rearrangements: new approaches toward discovery of novel translocations in head and neck squamous cell carcinoma
Gachet et al. Deletion 6q drives T-cell leukemia progression by ribosome modulation
Farin et al. Colorectal cancer organoid–stroma biobank allows subtype-specific assessment of individualized therapy responses
Yamazaki et al. Endogenous APOBEC3B overexpression constitutively generates DNA substitutions and deletions in myeloma cells
US20190360029A1 (en) A method of targeting patient-specific oncogenes in extrachromosomal dna to treat glioblastoma
Gimenez-Xavier et al. Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells
Joshi et al. Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations
Janz et al. Germline risk contribution to genomic instability in multiple myeloma
Gu et al. High immune cytolytic activity in tumor‐free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue
Wu et al. METTL3-mediated m6A modification controls splicing factor abundance and contributes to aggressive CLL
WO2023109875A1 (en) Biomarkers for colorectal cancer treatment
Gajduskova et al. Genome position and gene amplification
Nokin et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Gabel et al. Multiplexed screening reveals how cancer-specific alternative polyadenylation shapes tumor growth in vivo
Aiderus et al. Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression
WO2023284736A1 (en) Biomarkers for colorectal cancer treatment
Alsaadi Identification and validation of mutated signalling pathways in cancer
Nguyen et al. The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Repo et al. Functional assay for assessment of pathogenicity of BAP1 variants